US Stock MarketDetailed Quotes
ROIV Roivant Sciences
- 11.020
- -0.500-4.34%
Close Jan 8 16:00 ET
- 11.150
- +0.130+1.18%
Post 20:01 ET
8.02BMarket Cap1.89P/E (TTM)
11.500High10.990Low4.98MVolume11.400Open11.520Pre Close55.42MTurnover1.33%Turnover Ratio2.11P/E (Static)727.95MShares13.05552wk High1.56P/B4.14BFloat Cap9.69052wk Low--Dividend TTM375.23MShs Float16.760Historical High--Div YieldTTM4.43%Amplitude2.520Historical Low11.129Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Roivant Sciences Stock Forum
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinece...
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
6 minutes ago, 4:00 AM PST
Via GlobeNewswire
ROIVROIVW
Share
• Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosis
• Further development of namilumab for the treatment of sarcoidosis will be discontinued
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...
Gapping up
$DoorDash (DASH.US)$ stock rose 0.4% after CFRA Research upgraded its investment stance on the food delivery platform to buy from hold, citing its high growth potential.
$Roivant Sciences (ROIV.US)$ stock rose 7.2% after the biotech said its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study.
Gapping down
$NIO Inc (NIO.US)$ fell ...
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2 ...
Bill Ackman Cashes Out Bet Against Treasury Bonds as Yields Hit 16-year Highs
One of Wall Street's most prominent bond bears has decided to walk away with his gains, declaring that Treasury yields are likely poised for a turnaround following an ascent that rattled global markets.
Pershing Square's Bill Ackman said Monday that he has closed his bet against 30-year Treasury bonds, saying in a ser...
No comment yet